MDM2 and breast neoplasm: The p53 status of breast cancers occurring in our subjects is however currently unknown and it is therefore possible that an association between accelerated tumour development and MDM2 SNP309 would be found if analyses were restricted to BRCA1 mutation carriers with evidence of associated p53 protein abnormalities in the breast tumour.